Achillion: Corporate Presentation (Achillion) - Feb 13, 2015 - Anticipated presentation of data from P1 proof of concept trial in hepatitis C infection in H1 2015; Anticipated initiation of P2 SPARTA doublet program in combination with ACH-3102 for hepatitis C infection in H1 2015; Anticipated data from P2 SPARTA doublet trial in combination with ACH-3102 for hepatitis C infection in H2 2015; Anticipated initiation of multi-dose pharmacokinetic study in combination with ACH-3102 and sovaprevir for hepatitis C infection in H2 2015
Anticipated new P2 trial • Anticipated new trial • Anticipated P1 data • Anticipated P2 data • Hepatitis C Virus
|